MEDICINA
Departamento
Oregon Health & Science University
Portland, Estados UnidosPublicaciones en colaboración con investigadores/as de Oregon Health & Science University (12)
2024
-
Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
Dermatology and Therapy, Vol. 14, Núm. 3, pp. 593-612
2023
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437
2022
2021
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19
New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802
2020
-
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509
-
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 509-518
-
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893
2018
-
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR
Haematologica, Vol. 103, Núm. 12, pp. 2079-2087
-
Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density
Annals of the rheumatic diseases, Vol. 77, Núm. 3, pp. 378-385
2016
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial
The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051